Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital image

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Posted on: Jul 14, 2022
Play Episode
Also available on
play podcast in spotifySpotify play podcast in apple podcastsApple Podcasts
Description

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728

*You need to join by phone if you want to ask Dr. Shallis your questions.*

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the research indicates progress is being made in this area. 

Join us live on Thursday, July 14th at 11 am EST to hear from Dr. Rory Shallis with Yale New Haven Hospital who will be discussing the TP53 mutation in AML, current treatment options available, and the latest research and clinical trials using novel investigational agents to target this mutation. There will be time at the end of the show to ask Dr. Shallis your questions directly!

Thank you to our episode sponsor, Bristol Myers Squibb.

Overview

Rory Shallis, MD
Yale Cancer Center
Interview Date: July 14, 2022

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a poor prognosis, however, the research indicates progress is being made in this area. 

In this show, Dr. Rory Shallis, an AML expert from Yale Cancer Center, summarizes the TP53 mutation, the challenges it presents and the importance of clinical trials in the treatment of this mutation. Dr. Shallis covers several new drugs in development to consider as part of your treatment options available for this mutation.

Thanks to Our Episode Sponsor

User uploaded media

On this episode
Healthtree contact Kerith Amen

Kerith Amen

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Healthtree contact Rory Shallis, MD

Rory Shallis, MD

Dr. Shallis is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. He is an author on more than 75 peer-reviewed publications and book chapters, most of which he was first author on. His work has been published in many prestigious journals.
Transcript

Related Content